Dehradun Pharma Plant Continues Operating Despite CDSCO-Recommended Shutdown
Daffohils Laboratories in Selaqui has kept operating months after a CDSCO inspection recommended an immediate halt over manufacturing violations, with no public record of any shutdown order being issued or enforced.
Current Summary
A Central Drugs Standard Control Organisation (CDSCO) inspection in July 2026 recommended an immediate halt to all manufacturing at Daffohils Laboratories Private Limited, a pharmaceutical plant in Dehradun's Selaqui industrial area that makes tablets, capsules, dry syrups, ointments, creams and dusting powders. The inspection followed a confidential complaint sent in March 2026 to the office of Drugs Controller General of India Rajeev Singh Raghuvanshi, alleging serious Good Manufacturing Practices violations across 12 broad categories, including no environmental monitoring, poor monitoring of pharmaceutical water systems and incomplete testing of raw materials. Regulatory records reviewed by BusinessLine do not show whether a formal shutdown order was ever issued, whether the company halted production, or what action the state drug regulator took. The company has continued functioning.
What We Know
- CDSCO recommended an immediate manufacturing halt at Daffohils Laboratories in Selaqui, Dehradun, in July 2026.
- The recommendation followed a March 2026 complaint alleging 12 categories of Good Manufacturing Practices violations.
- There is no public record confirming a shutdown order was issued or that production stopped.
- The plant has continued operating since the recommendation.
What Is Still Unclear
- Whether the state drug regulator issued any formal order following the CDSCO recommendation.
- Whether the company has made any changes to its manufacturing practices.
- What products from the plant, if any, remain in the market.
What Changed
- 5 Nov, 02:42 pmSignal detected: Dehradun Pharma Plant Continues Operating Despite CDSCO-Recommended Shutdown